Similar articles for PMID: 26604650

Year	Number of Results
2002	1
2012	8
2013	13
2014	37
2015	55
2016	59
2017	57
2018	27
2019	8
2020	10
2021	9
2022	6
2023	3
2024	0

1

Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugs.

Hartman J, Bichoupan K, Patel N, Chekuri S, Harty A, Dieterich D, Perumalswami P, Branch AD. Hartman J, et al. World J Gastroenterol. 2015 Nov 21;21(43):12430-8. doi: 10.3748/wjg.v21.i43.12430. World J Gastroenterol. 2015. PMID: 26604650 Free PMC article.

2

Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV.

Del Bello D, Cha A, Sorbera M, Bichoupan K, Levine C, Doyle E, Harty A, Patel N, Ng M, Gardenier D, Odin J, Schiano TD, Fierer DS, Berkowitz L, Perumalswami PV, Dieterich DT, Branch AD. Del Bello D, et al. Clin Infect Dis. 2016 Jun 15;62(12):1497-1504. doi: 10.1093/cid/ciw119. Epub 2016 Mar 1. Clin Infect Dis. 2016. PMID: 26936665 Free PMC article.

3

Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.

Hagan LM, Sulkowski MS, Schinazi RF. Hagan LM, et al. Hepatology. 2014 Jul;60(1):37-45. doi: 10.1002/hep.27151. Epub 2014 May 14. Hepatology. 2014. PMID: 24677184 Free PMC article.

4

Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STIly observational study.

Gaeta GB, Aghemo A, Menzaghi B, D'Offizi G, Giorgini A, Hasson H, Brancaccio G, Palma M, Termini R; STIly Study Group. Gaeta GB, et al. Medicine (Baltimore). 2018 Jul;97(27):e11307. doi: 10.1097/MD.0000000000011307. Medicine (Baltimore). 2018. PMID: 29979400 Free PMC article.

5

Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen.

Hézode C, Chevaliez S, Scoazec G, Soulier A, Varaut A, Bouvier-Alias M, Ruiz I, Roudot-Thoraval F, Mallat A, Féray C, Pawlotsky JM. Hézode C, et al. Hepatology. 2016 Jun;63(6):1809-16. doi: 10.1002/hep.28491. Epub 2016 Mar 10. Hepatology. 2016. PMID: 26853230 Clinical Trial.

6

Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens.

Maasoumy B, Vermehren J, Welker MW, Bremer B, Perner D, Höner Zu Siederdissen C, Deterding K, Lehmann P, Cloherty G, Reinhardt B, Pawlotsky JM, Manns MP, Zeuzem S, Cornberg M, Wedemeyer H, Sarrazin C. Maasoumy B, et al. J Hepatol. 2016 Sep;65(3):473-82. doi: 10.1016/j.jhep.2016.04.006. Epub 2016 Apr 13. J Hepatol. 2016. PMID: 27085252

7

Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin.

Shiffman ML, James AM, Long AG, Alexander PC. Shiffman ML, et al. Am J Gastroenterol. 2015 Aug;110(8):1179-85. doi: 10.1038/ajg.2015.218. Epub 2015 Jul 28. Am J Gastroenterol. 2015. PMID: 26215530

8

Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.

Fontana RJ, Brown RS Jr, Moreno-Zamora A, Prieto M, Joshi S, Londoño MC, Herzer K, Chacko KR, Stauber RE, Knop V, Jafri SM, Castells L, Ferenci P, Torti C, Durand CM, Loiacono L, Lionetti R, Bahirwani R, Weiland O, Mubarak A, ElSharkawy AM, Stadler B, Montalbano M, Berg C, Pellicelli AM, Stenmark S, Vekeman F, Ionescu-Ittu R, Emond B, Reddy KR. Fontana RJ, et al. Liver Transpl. 2016 Apr;22(4):446-58. doi: 10.1002/lt.24416. Liver Transpl. 2016. PMID: 26890629 Free article.

9

Two patients treated with simeprevir plus pegylated-interferon and ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation: case report.

Kawaoka T, Imamura M, Kan H, Fujino H, Fukuhara T, Kobayashi T, Honda Y, Naeshiro N, Hiramatsu A, Tsuge M, Hayes CN, Kawakami Y, Aikata H, Ochi H, Ishiyama K, Tashiro H, Ohdan H, Chayama K. Kawaoka T, et al. Transplant Proc. 2015 Apr;47(3):809-14. doi: 10.1016/j.transproceed.2014.10.052. Transplant Proc. 2015. PMID: 25891736

10

HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients.

Salmon D, Bani-Sadr F, Gilbert C, Rosenthal E, Valantin MA, Simon A, Neau D, Morlat P, Loko MA, Wittkop L, Dabis F; ANRS CO13HEPAVIH study group. Salmon D, et al. J Clin Virol. 2015 Dec;73:32-35. doi: 10.1016/j.jcv.2015.10.010. Epub 2015 Oct 19. J Clin Virol. 2015. PMID: 26528903

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

264 results

Results by year